Cargando…

P993: INCREASED STAT5B LEVELS IN MYELOPROLIFERATIVE NEOPLASMS LEAD TO ENHANCED MEGAKARYOCYTIC DIFFERENTIATION CORRELATING WITH THROMBOSIS

Detalles Bibliográficos
Autores principales:	Ploderer, Marie, Maurer, Barbara, Schreiberhuber, Lena, Suske, Tobias, Feurstein, Gabriela, Song, Jihyun, Prchal, Josef, Moriggl, Richard, Neubauer, Heidi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431351/ http://dx.doi.org/10.1097/01.HS9.0000970876.19398.b4

Ejemplares similares

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Targeting megakaryocytic induced fibrosis by AURKA inhibition in the myeloproliferative neoplasms
por: Wen, Qiang Jeremy, et al.
Publicado: (2015)

Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas
por: Orlova, Anna, et al.
Publicado: (2017)

Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms
por: Malherbe, Jacques A J, et al.
Publicado: (2016)

Presence of Polyclonal Hematopoiesis in Females with Ph-negative Myeloproliferative Neoplasms
por: Swierczek, Sabina, et al.
Publicado: (2015)

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
por: Ghai, Shuchi, et al.
Publicado: (2017)

Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms
por: Schino, Mattia, et al.
Publicado: (2020)

Antiphospholipid antibodies and the risk of thrombosis in myeloproliferative neoplasms
por: Dambrauskienė, Rūta, et al.
Publicado: (2023)

Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens
por: Mosale Seetharam, Sumanth, et al.
Publicado: (2023)

Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens
por: Seetharam, Sumanth Mosale, et al.
Publicado: (2023)

Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin
por: Li, Geqiang, et al.
Publicado: (2010)

STAT5B(N642H) drives transformation of NKT cells: a novel mouse model for CD56(+) T-LGL leukemia
por: Klein, Klara, et al.
Publicado: (2019)

Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms
por: Ferrer-Marín, Francisca, et al.
Publicado: (2021)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

Bibliomex salud, l993
Publicado: (1994)

Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53
por: Chernak, Brian J., et al.
Publicado: (2020)

Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations
por: Ali, Hebah, et al.
Publicado: (2020)

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
por: Barbui, Tiziano, et al.
Publicado: (2022)

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm
por: Görtzen, Jan, et al.
Publicado: (2016)

Patients with myeloproliferative neoplasms and COVID‐19 have increased rates of arterial thrombosis
por: Leiva, Orly, et al.
Publicado: (2022)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes
por: Balduini, Alessandra, et al.
Publicado: (2011)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

STAT5 is Expressed in CD34(+)/CD38(−) Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms
por: Hadzijusufovic, Emir, et al.
Publicado: (2020)

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
por: Liu, Angela, et al.
Publicado: (2022)

Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
por: Borsani, Oscar, et al.
Publicado: (2022)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms
por: Bekendam, Roelof H., et al.
Publicado: (2023)

Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
por: Čokić, Vladan P., et al.
Publicado: (2015)

Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19
por: Leiva, Orly, et al.
Publicado: (2021)

Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation
por: Wang, Steven, et al.
Publicado: (2016)

Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms
por: Vladareanu, AM, et al.
Publicado: (2011)

Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists
por: Fedorov, Kateryna, et al.
Publicado: (2021)

Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms
por: Kelliher, Sarah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a9114jdbsuti7qr50p38orbkh8